Patents by Inventor Olav Michael Andersen

Olav Michael Andersen has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • A DRUG SCREENING PLATFORM FOR ENDOSOMAL ENHANCERS TO TREAT ALZHEIMER'S DISEASE
    Publication number: 20230235017
    Abstract: The present invention relates to a sorLA-based drug screening platform for use in screening compound libraries for an effect on endosomal activity.
    Type: Application
    Filed: June 15, 2021
    Publication date: July 27, 2023
    Inventor: Olav Michael Andersen
  • Modulation of Activity of Proneurotrophins
    Publication number: 20160060346
    Abstract: The present invention provides agents for inhibiting binding of a pro-neurotrophin to a Vps10p-domain receptor, in particular the binding of a pro-NGF or a pro-BDNF to a Sortilin receptor. The invention thus provides agents for the manufacture of a medicament, for treating and/or preventing disease or disorders such as but not limited to neurological, neuropsychiatric and ocular diseases, disorders, and degeneration as well as obesity, diabetes, pain and/or nociception in an individual.
    Type: Application
    Filed: November 16, 2015
    Publication date: March 3, 2016
    Applicant: H. LUNDBECK A/S
    Inventors: Olav Michael Andersen, Anders Nykjær
  • Modulation of Activity of Proneurotrophins
    Publication number: 20150023971
    Abstract: The present invention provides agents for inhibiting binding of a pro-neurotrophin to a Vps1 Op-domain receptor, in particular the binding of a pro-NGF or a pro-BDNF to a Sortilin receptor. The invention thus provides agents for the manufacture of a medicament, for treating and/or preventing disease or disorders such as but not limited to neurological, neuropsychiatric and ocular diseases, disorders, and degeneration as well as obesity, diabetes, pain and/or nociception in an individual.
    Type: Application
    Filed: April 25, 2014
    Publication date: January 22, 2015
    Applicant: H LUNDBECK A/S
    Inventors: Olav Michael Andersen, Anders Nykjaer
  • Modulation of activity of proneurotrophins
    Patent number: 8748384
    Abstract: The present invention provides agents for inhibiting binding of a pro-neurotrophin to a Vps1 Op-domain receptor, in particular the binding of a pro-NGF or a pro-BDNF to a Sortilin receptor. The invention thus provides agents for the manufacture of a medicament, for treating and/or preventing disease or disorders such as but not limited to neurological, neuropsychiatric and ocular diseases, disorders, and degeneration as well as obesity, diabetes, pain and/or nociception in an individual.
    Type: Grant
    Filed: December 21, 2007
    Date of Patent: June 10, 2014
    Assignee: H. Lundbeck A/S
    Inventors: Olav Michael Andersen, Anders Nykjaer
  • MODULATION OF ACTIVITY OF PRONEUROTROPHINS
    Publication number: 20100210523
    Abstract: The present invention provides agents for inhibiting binding of a pro-neurotrophin to a Vps10p-domain receptor, in particular the binding of a pro-NGF or a pro-BDNF to a Sortilin receptor. The invention thus provides agents for the manufacture of a medicament, for treating and/or preventing disease or disorders such as but not limited to neurological, neuropsychiatric and ocular diseases, disorders, and degeneration as well as obesity, diabetes, pain and/or nociception in an individual.
    Type: Application
    Filed: December 21, 2007
    Publication date: August 19, 2010
    Applicant: NeuronIcon ApS
    Inventors: Olav Michael Andersen, Anders Nykjær